Analysts have shifted to a more constructive posture on the managed care sector, moving Humana, Centene and Elevance Health to Buy ratings while lowering The Cigna Group to Hold on valuation grounds. The revisions follow several years during which Medicare and Medicaid cost growth put pressure on MCO profitability.
According to the analysts' notes, the upgrades stem from growing confidence that managed care organizations have adapted to the sector's so-called "rate-chasing-risk" cycle and are now better positioned to rebuild margins through firmer underwriting and more disciplined product pricing. They cited evidence that healthcare utilization trends - a principal driver of cost inflation for insurers - may have peaked, enabling companies to align pricing more effectively with higher medical costs.
The change in tone represents a notable move away from the caution that had characterized investor sentiment toward health insurers in recent years. Analysts said they are increasingly comfortable taking a constructive view on the sector as pricing discipline improves and margin recovery becomes more visible.
Company-specific notes
Humana was upgraded to Buy, with its price target raised sharply to $441 from $235. That target is derived from a multiple of 12 times the firm's revised 2028 earnings estimate of $36.74 per share, a forecast that incorporates an anticipated recovery in the company's Medicare Star Ratings performance. Analysts noted that 2026 could serve as an earnings bottom and a "rebasing" year for Humana, though they warned the company still faces meaningful uncertainty tied to its Stars ratings outcome, which is expected in October 2026.
Centene was moved up to Buy from Hold, and its target price was increased to $80 from $53. The valuation supporting the new target is based on 12 times projected 2028 earnings of $6.70 per share. Analysts said they reduced the valuation multiple from 15 times to 12 times to reflect a longer time horizon before the company's earnings recovery is fully realized beyond 2027.
Elevance Health was upgraded to Buy as well, with the target price lifted to $498 from $363. That new target corresponds to 14.5 times projected 2028 earnings of $34.34 per share.
Sector outlook
Analysts emphasized that these rating changes reflect both improved pricing discipline across products and expectations that utilization-driven cost inflation may have reached its peak. The combination, they argue, should allow MCOs to pursue stronger underwriting outcomes and rebuild margins over the next several years.
Bottom line
The cluster of upgrades signals a broader shift in analyst sentiment toward managed care, with select insurers now viewed as positioned to recover earnings as pricing and utilization trends normalize. Still, company-specific uncertainties - notably Humana's dependence on Medicare Star Ratings - remain potential derailers of the anticipated recovery.